Home   /  Find a Trial  /  See All TrialsHELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Preventing Breast Cancer

Metformin For Reducing Breast Cancer Risk in Overweight Premenopausal Women

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk (NCT02028221)

Summary

Women who are overweight are at greater risk of developing breast cancer after menopause. Doctors think this may be because being overweight is linked to a "metabolic syndrome" that increases hormone levels and inflammation. Previous research findings suggest that metformin, a drug commonly used to treat type 2 diabetes, may reduce breast cancer risk. This study is looking at whether metformin is more effective than a placebo at reducing breast cancer risk in overweight premenopausal women who have a BMI ≥25.
This is a Phase II trial

Telapristone Before Mastectomy for High-Risk, DCIS or Stage I-II Breast Cancer

Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy (NCT02314156)

Summary

Telapristone is an anti-progesterone drug. Laboratory studies have found telapristone can prevent tumors from growing. Telapristone can be given as a pill or absorbed into the skin through a patch. Researchers want to see if giving telapristone before surgery can help prevent breast cancer in premenopausal women. This study is comparing the effectiveness of a telapristone pill or patch to a placebo pill or patch for preventing breast cancer in high-risk women and reducing risk of recurrence in women with DCIS or stage I-II breast cancer. To be eligible, a woman must be premenopausal and scheduled to have a unilateral or bilateral mastectomy.
This is a Phase II trial

Effect of Olive Oil on Breast Density in High-Risk Women

A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer (NCT02068092)

Summary

Studies have shown that women with dense breast tissue are at increased risk for developing breast cancer. Laboratory studies have found that hydroxytyrosol--a major component of olive oil--is a powerful antioxidant with very low toxicity in the human body, even at high doses. Researchers think that hydroxytyrosol may reduce dense breast tissue. This study will evaluate the effect that hydroxytyrosol has on the breast tissue of women who are at high risk for developing breast cancer.

Effect of Tumeric on Breast Tissue in Obese, High-Risk Women

Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial (NCT01975363)

Summary

Laboratory studies suggest that tumeric (curcumin) may have anti-cancer effects. This may be because tumeric can reduce inflammation, which has been linked to cancer growth. Researchers think that tumeric may reduce inflammation in fat tissue and breast tissue, which may decrease breast cancer risk. This pilot study is looking at the effect that tumeric has on the breast tissue of obese women who are at high risk for breast cancer.

Using Breast Duct Cells to Assess Cancer Risk

Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile (NCT00028340)

Summary

Most breast cancers begin in the cells that line the milk ducts in the breast. Previous studies have identified certain changes in the ductal cells and breast tissue that are associated with an increased risk of developing breast cancer. Ductal lavage and ductal endoscopy are techniques that allow researchers to study the cells and fluid that line the breast duct. In this study, researchers will use ductal lavage and ductal endoscopy to compare the ductal cells and tissue of women who are at high risk for breast cancer, breast cancer survivors and healthy volunteers.

The Effect of a Time Restricted Diet on Weight Control, Hormones and Breast Tissue

A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women (NCT02154984)

Summary

Women who are overweight are at increased risk of developing breast cancer. A time-restricted diet is a type of diet that requires people to restrict their daily eating to a specific time frame each day. This study is looking at whether a time-restricted diet is easy for women to maintain and what effect it has on weight, hormones and breast tissue. To be eligible, a woman must have a stable weight and have a body-mass index (BMI) of 25-40.

Fosamax Before Preventive Mastectomy in High-Risk Women or Women with DCIS

Pilot Clinical Trial of Short-Term Bisphosphonate Administration as Chemoprevention for Breast Cancer Via Engagement of γδ T Cells (NCT02781805)

Summary

To take part in this study, you must be scheduled to have a preventive (prophylactic) mastectomy of one or both breasts because you are at high risk for developing breast cancer or because you have been diagnosed with ductal carcinoma in situ (DCIS). You must also be premenopausal (still have your period). Alendronate (Fosamax) is a drug used to help maintain bone strength. Studies suggest this drug may also have an effect on breast tissue and cancer cells. Giving a drug before surgery allows researchers to study the effect it has on breast tissue. If you take part in this study, you will take Fosamax before you have your mastectomy.
This is a Phase I trial

Effect of Vitamin D on Breast Cells in Women With DCIS or LCIS

An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS (NCT02936999)

Summary

DCIS is a non-invasive breast cancer. Non-invasive means it has not spread out of the milk duct into the breast tissue. LCIS is an area of abnormal cell growth. Having DCIS or LCIS increases your risk for developing breast cancer. In this study, researchers will have women with LCIS or DCIS take vitamin D before surgery. The researchers will then study the tissue removed during surgery to see the effect the vitamin D has had on the breast cells.

Metformin to Reduce Breast Cancer Risk in Women with Atypical Hyperplasia, DCIS or LCIS

Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1,1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women (NCT01905046)

Summary

Women who have been diagnosed with atypical hyperplasia, DCIS or LCIS are at increased risk of developing breast cancer. Researchers are trying to find drugs (chemoprevention) that can reduce this risk. Findings from previous studies suggest that metformin, a drug used to treat diabetes, can reduce breast cancer risk in high-risk women. This study is looking at whether metformin is better than a placebo at reducing breast cancer risk in women with atypical hyperplasia, DCIS or LCIS. To be eligible, a woman must have had a digital mammogram within the previous 180 days and have a BMI ≥25 (overweight).
This is a Phase III trial

Studying Breast Milk & Cancer Risk in African-American Women

Epigenetics and Breast Cancer Risk in African American Women (NCT01736306)

Summary

Pregnancy and breastfeeding are believed to influence breast cancer risk. Studying cells found in breast milk may provide clues to the genetic changes that increase breast cancer risk. To date, most of the breast milk studied has been collected from white women. Collecting and analyzing breast milk samples from African-American women, and following these women to see who goes on to develop breast cancer, could help researchers learn more about breast cancer risk. To be eligible, participants must identify as African-American, Black, or African; be currently nursing a baby; and have had or be scheduled to have a breast biopsy. (Women who do not identify as African-American, Black or African can participate in another ongoing Breast Milk Study at the University of Massachusetts.)

  • Participation TimeVia U.S. Mail
  • No Visits Required for this TrialNo travel required 

Multiplex Genetic Testing for Evaluation of Breast Cancer Risk

Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study (NCT02514499)

Summary

Multiplex genetic testing can look for many different gene mutations, rather than just one or two. Researchers are evaluating the short- and long-term benefits and risks of multiplex testing in individuals who are at high risk for developing breast cancer and BRCA1/2 negative. This study will investigate what factors affect an individual's decision to receive genetic test results and what factors affect outcomes after the participants receive their results. The researchers will use their findings to determine the best way to provide support to individuals undergoing multiplex testing.